Skip to main content
OpenTrials
Completed

NCT Number: NCT02743247

Identification of Drug-drug Interaction Between Tacrolimus and Mycophenolate Mofetil in Healthy Adults

Coadministration of tacrolimus and mycophenolate mofetil is frequent in kidney transplantation. Due to narrow therapeutic range of tacrolimus and mycophenolate mofetil, therapeutic drug monitoring with dose adjustment is required. Investigating pharmacokinetic interplay between two drugs enables fine dose adjustment, while mechanism of drug interaction between two drugs is still not well understood. Therefore, an open-label, three period, single dose trial is planned to investigate the drug interaction between tacrolimus and mycophenolate mofetil.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

19 year–45 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

Seoul National University Hospital

Seoul, 110-744, South Korea

About this study

Study consists of three periods with fixed sequence: 1) single dose of mycophenolate mofetil 1,000mg; 2) single dose of tacrolimus 5mg; 3) single dose of mycophenolate mofetil 1,000mg and tacrolimus 5mg. All subjects have one week of washing period between single dose administration. Blood samples are drawn up to 72 hours after drug administration. Single nucleotide polymorphisms known to result in pharmacokinetic variability of study drug are also investigated. Drug interaction is going to be assessed through the ratio of area under the concentration curve of one drug in the presence or absence of another drug.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male adult with age of 19-45
  • Weight difference between ideal and actual body weight is less than 20%
  • Previous healthy with no known disease
  • Considered normal on physical exam, clinical laboratory tests(complete blood count, electrolyte, renal and hepatic function) and electrocardiogram
  • Never been heavy-drinker within one month prior to trial initiation and able to abstain from alcohol during trial

Exclusion criteria

  • Ever smoked within one year prior to trial initiation
  • Took other drugs (including herbal medicine) within one month prior to trial initiation
  • Alcohol or drug abuser
  • Participated another clinical trial within three months
  • Considered inadequate under investigator's discretion

Treatment and study plan

Tacrolimus

Drug

Other names: Prograf

Mycophenolate mofetil

Drug

Other names: Cellcept

Primary outcomes

  1. Area under the concentration versus time curve (AUC) of Tacrolimus and Mycophenolate mofetil

    Time frame: 0, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours post-dose

Secondary outcomes

  1. Peak Concentration of Tacrolimus and Mycophenolate mofetil

    Time frame: 0, 1, 2, 4, 6, 8, 12, 24, 48, 72 hours post-dose

  2. Adverse Drug Reaction

    Time frame: through study completion, an average of 1 month

Sponsors and collaborators

Lead sponsor

Seoul National University Hospital

Other

Collaborators

  • Ministry of Food and Drug Safety, Korea

Registry information

Important dates

Study start
2015
Primary completion
2016
Study completion
2016
First posted
Apr 19, 2016
Registry last updated
Apr 19, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.